Get the Stockscreener App
13.83
1.17%
0.16
After Hours:
13.83
Denali Therapeutics Inc stock is traded at $13.83, with a volume of 1.90M.
It is up +1.17% in the last 24 hours and down -1.14% over the past month.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
See More
Previous Close:
$13.67
Open:
$13.435
24h Volume:
1.90M
Relative Volume:
1.28
Market Cap:
$2.01B
Revenue:
$340.81M
Net Income/Loss:
$-419.65M
P/E Ratio:
-4.8526
EPS:
-2.85
Net Cash Flow:
$-402.10M
1W Performance:
-3.35%
1M Performance:
-1.14%
6M Performance:
-40.64%
1Y Performance:
-43.25%
1-Day Range:
$13.44
$14.13
1-Week Range:
$13.44
$14.71
52-Week Range:
$10.57
$33.33
Denali Therapeutics Inc Stock (DNLI) Company Profile
Name
Denali Therapeutics Inc
Sector
Industry
Phone
(650) 866-8547
Address
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
Compare DNLI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DNLI
Denali Therapeutics Inc
|
13.83 | 1.99B | 340.81M | -419.65M | -402.10M | -2.85 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-07-25 | Resumed | Morgan Stanley | Overweight |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Jan-07-25 | Initiated | Robert W. Baird | Outperform |
| Jan-03-25 | Initiated | William Blair | Outperform |
| Dec-16-24 | Upgrade | Stifel | Hold → Buy |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Oct-07-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Dec-13-23 | Initiated | Citigroup | Buy |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Sep-06-23 | Initiated | B. Riley Securities | Buy |
| Jan-30-23 | Initiated | SVB Securities | Outperform |
| Dec-05-22 | Initiated | Cowen | Outperform |
| Nov-02-22 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-02-22 | Initiated | BofA Securities | Buy |
| Jun-23-22 | Initiated | Berenberg | Buy |
| Dec-10-21 | Resumed | Raymond James | Mkt Perform |
| Sep-21-21 | Initiated | Oppenheimer | Outperform |
| Sep-01-21 | Initiated | SMBC Nikko | Outperform |
| May-18-21 | Initiated | UBS | Buy |
| Feb-26-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-10-21 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Nov-11-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-16-20 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Aug-20-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-13-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-28-20 | Upgrade | Wedbush | Neutral → Outperform |
| Feb-24-20 | Initiated | Jefferies | Buy |
| Feb-19-20 | Initiated | Stifel | Hold |
| Jan-27-20 | Upgrade | Goldman | Neutral → Buy |
| Sep-26-19 | Initiated | Wedbush | Neutral |
| Sep-13-19 | Initiated | Nomura | Buy |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jun-26-19 | Initiated | H.C. Wainwright | Buy |
| Nov-15-18 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-12-18 | Initiated | Janney | Buy |
| Mar-12-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Jan-02-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Initiated | Goldman | Neutral |
| Jan-02-18 | Initiated | JP Morgan | Overweight |
| Jan-02-18 | Initiated | Morgan Stanley | Overweight |
View All
Denali Therapeutics Inc Stock (DNLI) Latest News
Does Denali Therapeutics Inc. stock perform well during market downturnsPost Market Picks With Low Risk - jammulinksnews.com
Denali Therapeutics Inc. (DNLI) Secures FDA Priority Review for First-Ever Brain-Penetrant Hunter Syndrome Therapy - Insider Monkey
What makes Denali Therapeutics Inc. stock price move sharplyTop Growth Planner For Every Investor - jammulinksnews.com
What is Denali Therapeutics Inc. company’s growth strategyFree Stock Insights For Every Investor - jammulinksnews.com
Price momentum metrics for Denali Therapeutics Inc. explainedStock Portfolio Allocation Guidance for Volatile Markets - metal.it
11 Best Future Stocks to Buy Now - Insider Monkey
Can Denali Therapeutics Inc. Rally Enough to Break EvenReal Profit Trade Plan Suggestions Shared Widely - metal.it
Is Denali Therapeutics Inc. a growth stock or a value stockBest Dividend Data Feed Backed By Experts - jammulinksnews.com
Volume Surge May Signal Institutional Interest in Denali Therapeutics Inc.Trade Setups With Clear Risk Limits Highlighted - metal.it
What are analysts’ price targets for Denali Therapeutics Inc. in the next 12 monthsMaximize returns with expert trading insights - jammulinksnews.com
Is it the right time to buy Denali Therapeutics Inc. stockAccess powerful market insights for free - jammulinksnews.com
What are the technical indicators suggesting about Denali Therapeutics Inc.Real Time Guidance For 2025 - jammulinksnews.com
How volatile is Denali Therapeutics Inc. stock compared to the marketGet exclusive market analysis for investors - jammulinksnews.com
How does Denali Therapeutics Inc. generate profit in a changing economyUnlock powerful stock screening tools today - jammulinksnews.com
Is Denali Therapeutics Inc. stock overvalued or undervaluedGet timely alerts on top-performing stocks - jammulinksnews.com
What is the risk reward ratio of investing in Denali Therapeutics Inc. stockBoost your returns with professional guidance - jammulinksnews.com
How strong is Denali Therapeutics Inc. company’s balance sheetCapitalize on market momentum for maximum profit - jammulinksnews.com
Published on: 2025-07-27 16:21:55 - jammulinksnews.com
BTIG Reiterates a Buy Rating on Denali Therapeutics (DNLI) With a $32 Price Target - MSN
What drives Denali Therapeutics Inc. stock priceRapid growth opportunities - PrintWeekIndia
Why Denali Therapeutics Inc. stock is on top investor watchlistsStrongest growth potential - jammulinksnews.com
Will Denali Therapeutics Inc. stock benefit from interest rate changesFree Investment Community - jammulinksnews.com
What analysts say about Denali Therapeutics Inc. stockOutstanding capital growth - Autocar Professional
Is Denali Therapeutics Inc. a good long term investmentOutperformance with explosive growth - jammulinksnews.com
Denali Therapeutics Inc. Stock Analysis and ForecastRapidly expanding wealth - jammulinksnews.com
Denali Therapeutics Inc Stock (DNLI) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):